Drugs / SC1011
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06135363 | Aug 2022 → Jan 2023 | idiopathic pulmonary fibrosis | Guangzhou JOYO Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06160440 | Jun → Sep 2021 | idiopathic pulmonary fibrosis, pulmonary fibrosis | Guangzhou JOYO Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06125327 | Jun 2023 → Dec 2026 expected | idiopathic pulmonary fibrosis | Guangzhou JOYO Pharma Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06125327 ↗ |
| Route | Oral | “Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.” NCT06125327 ↗ |